Speakers who nominally represent cancer patients at advisory meetings on new drugs often have financial ties with the company seeking marketing approval. And those ties aren’t always disclosed, according to an analysis.
Speakers who nominally represent cancer patients at advisory meetings on new drugs often have financial ties with the company seeking marketing approval. And those ties aren’t always disclosed, according to an analysis.